This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Oligonucleotide API Market

Market Insights on Oligonucleotide API covering sales outlook, demand forecast & up-to-date key trends

Oligonucleotide API Market by API, Marketing Status, End User & Region - Forecast 2022-2030

Oligonucleotide API Market Outlook (2022-2030)

[181 Pages Report] Owing to the growing need for new drug classes, demand for oligonucleotide APIs is projected to rise at a high CAGR of 10.2% from 2022 to 2030. As such, the global oligonucleotide API market is projected to increase from a valuation of US$ 2.46 Bn in 2022 to US$ 5.36 Bn by the end of 2030.

Oligonucleotide API Market Size (2022)

US$ 2.46 Bn

Revenue Forecast (2030)

US$ 5.36 Bn

Global Market Growth Rate (2022-2030)

10.2% CAGR

North America Market Share

39.9%

Oligonucleotide APIs currently account for 35.6% share in the global oligonucleotide synthesis market. For the benefit of patients, key producers are concentrating on bringing in high-quality oligonucleotide APIs to the market.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

10.12%

H1, 2022 Projected

10.19%

H1, 2022 Outlook

10.09%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 10 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 03 ↓

According to Future Market Insights' analysis, the global oligonucleotide API market expects to drop by 03 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 projected value, the market during H1-2022 outlook period will show a dip of 10 BPS.

The market is subject to be influenced by several macro and industrial factors, including GMP guidelines, product licensing, pharmaceutical and drug regulations, and sustainability.

The value in BPS change observes a negative impact owed to the fact that in the current scenario, oligonucleotide production poses a cost and waste burden to the manufacturers. Moreover, oligonucleotide production is an energy intensive process and calls for extensive measures for the treatment of hazardous waste before disposal. These factors hinder the growth of the market and the associated BPS value change.

The market for oligonucleotide API will, however, develop gradually in terms of growth with advancements in large scale production practices, such as the development of an oligonucleotide synthesizer.

Oligonucleotide API Demand Analysis (2015 to 2021) Vs Market Outlook (2022 to 2030)

Oligonucleotides are a new type of medicinal molecule that can be used to treat a wide range of ailments. They're little strands of mutated DNA, usually around 20 nucleotides long. Isolation of the active pharmaceutical ingredient (API) via lyophilization to produce a solid product, which is subsequently dissolved to produce an aqueous formulation, is the most typical method for producing oligonucleotides.

The oligonucleotide API market expanded at an astronomical CAGR of 23.8% from 2015 to 2021. Companies have used oligonucleotide active pharmaceutical ingredients (APIs) in solid solutions (powdered form) and, more recently, in the solution form.

Widespread use of oligonucleotide active pharmaceutical ingredients in the treatment of various ailments is driving the oligonucleotide API industry. Product development has paved the path for new therapeutic techniques in a range of treatment areas, including ophthalmologic indications, neuromuscular illnesses, and vaccine adjuvants.

Micro-RNA, small/short interfering RNA, Antisense oligonucleotides, immunostimulatory oligonucleotides, aptamers, and splice-switching oligonucleotides are some of the most important oligonucleotide classes. Solution stability, viscosity, concentration, end-to-end manufacturing, and packaging are some of the variables that have enhanced the trend of oligonucleotide APIs in solution.

The market for oligonucleotide APIs is looking brighter because of significant advancements achieved in the industry associations discussing CMC (chemistry, manufacturing, and control) techniques. Demand for novel drug classes for chronic obstructive pulmonary disease and asthma is increasing, opening up new market opportunities.

Sales of oligonucleotide APIs are expected to progress at a CAGR of 10.2% from 2022 to 2030, with the global market predicted to reach a valuation of US$ 5.36 Bn by 2030.

Oligonucleotide API Market Download Report Brochure

Which Factors are Boosting the Sales Growth of the Oligonucleotide API Market?

“Increasing Investments in R&D to Boost Oligonucleotide API Demand”

Increasing number of oligonucleotide active pharmaceutical ingredients in medication pipelines around the world is a major driver of market growth. Pharma businesses have benefited from the ongoing trend toward harmonization of oligonucleotide development and marketing over the last 10–15 years.

The European Pharma Oligonucleotide Consortium (EPOC) has made concentrated efforts with pharmaceutical businesses all over the world in this respect. The development of oligonucleotide therapies has been aided by a growing number of science-based suggestions. Increased research in biological treatments has bolstered Pharma companies’ medication pipelines in the oligonucleotide API market.

A comparison study of the solution versus powder API has helped market participants. The numerous advantages of powder API produced by the lyophilization process have enhanced its popularity. Several studies on retaining the stability of various oligonucleotide classes have aided the growth of the oligonucleotide API market.

Pharma businesses have benefited from advances in technologies for the concentration of oligonucleotide API solutions. Furthermore, the market for oligonucleotide active pharmaceutical ingredients is being boosted by the increasing usage of sophisticated chromatographic purification.

“Growing Fear of Cancer & Alzheimer Driving Development of Advanced Testing Procedures”

Due to the sheer rising number of cancer cases, the demand for innovative diagnostics is expected to rise. Oligonucleotide APIs pave the way for a brand-new class of nucleic acid probes known as "aptamers," which are outperforming monoclonal antibodies.

Personalized treatments are also needed for neurodegenerative diseases. During the projected timeframe, this trend is likely to have an impact on the oligonucleotide API market.

Degenerated nerves are more common in the elderly population. "Alzheimer's disease" is one of the most frequent neurodegenerative conditions. On this front, conventional medicine has several limits. As a result, a substantial study is being done on the use of oligonucleotide APIs in this field.

  • For example, LMTX, an anti-tau chemical, has been claimed to have the potential to improve cognitive capacities in Alzheimer's patients. The chemical was tested on mice, which produced tau protein that acted as an inhibitor of tau protein aggregation, slowing the progression of Alzheimer disease in mice.

Such kinds of discoveries are bound to persuade healthcare providers to use oligonucleotide APIs for other chronic diseases as well.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Regional Markets are Set to Be Lucrative for Oligonucleotide API Vendors?

“Increasing Funding in Drug Discovery to Boost Sales Growth of North America & Europe Oligonucleotide API Market”

The global oligonucleotide API market has been studied across North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).

North America is expected to hold 39.9% of the global market share, in 2022. The oligonucleotide API market is dominated by North America. This is due to its major presence in drug development, diagnostic screening, cancer, proteomics, and genomics.

Because Europe is home to the majority of the world's geriatric population, substantial research on the use of oligonucleotide APIs in treating disorders connected to ageing is being conducted. At present, Europe is predicted to account for 39.6% of the global market share.

Rise in revenue in the global API market can be ascribed to the rise in commercially authorised oligonucleotide therapies in North America and Europe. Latin America is set to account for 7.4% of the global market share in 2022.

In 2022, East Asia, South Asia and Oceania together are likely to hold 12% of the global market share. The Asia Pacific is a healthy regional market due to its growing funding for healthcare facilities.

The MEA region's oligonucleotide API market is likely to grow at a slower pace than other regions, however, this trend is expected to reverse by the end of the projected period. The MEA market is expected to account for 1.1% of the global market share in 2022.

Country-wise Analysis                                                       

How is the Oligonucleotide API Market Growing in the U.S.?

“Improved Healthcare Facilities Driving Oligonucleotide API Market Growth in the U.S.”

The United States is one of the top countries driving the oligonucleotide API market. According to the US FDA's Center for Drug Evaluation and Research, over 28% of API manufacturing facilities for the US market are located in the United States. The remaining 59 percent are based in other regions of the world, including 13 percent situated in China.

Thus, the country’s advanced healthcare infrastructure is helping in the expansion of the oligonucleotide API market. The U.S. is also focusing on larger investments in drug discovery programs.

Which Factors are Fueling Sales Growth of the China Oligonucleotide API Market?

“Massive Investments in Life Scientific Activities Make China a Prospective Market for Oligonucleotide APIs”

Due to significant spending on healthcare infrastructural development, the market for oligonucleotide active pharmaceutical ingredients is predicted to grow fast in the country.

Presence of various biopharmaceutical contractual research organisations in China, as well as the relocation of drug manufacturing plants by multinational manufacturers, are estimated to expand the market's optimistic growth prospects through 2030.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Analysis

Which API Type is in Most Demand?

“Antisense Oligonucleotides APIs Gaining Popularity Due to Their Effective Results”

The manufacture of oligonucleotides has always revolved around separating API and lyophilizing it to create a solid product. Following its dissolution, an aqueous formulation is generated.

In today's world, however, API manufacturers do not always need to isolate solid API before therapeutic product formulation. The European Pharma Oligonucleotide Consortium has partnered with many pharmaceutical companies to share CMC (chemical, manufacturing, and control) practices to harmonise oligonucleotide commercialization and development.

The "antisense" oligonucleotide class is gaining popularity. In the year 2016, they were certified for commercial use. Spinraza, Tegsedi, and Waylivra are some among them.

The advantage of solution APIs over powder APIs is that they place a greater emphasis on microbial control. Furthermore, the elimination of compounding and dissolution processes ensures improved efficiency.

COVID-19 Impact on Market

The COVID-19 pandemic harmed the production of oligonucleotide APIs. The COVID-19 outbreak momentarily dented the oligonucleotide API market, as production slowed due to partial/total lockdowns around the globe.

The market is predicted to recover over the coming years. Players will most likely invest more in oligonucleotide APIs in order to find long-term solutions to pandemics like this one.

Competitive Landscape

Sarepta Therapeutics, Akcea Therapeutics, Jazz Pharmaceuticals, Inc., Biogen, and Dynavax Technologies are the top participants in the oligonucleotide API industry. Through inorganic expansion methods, market players are focusing on expanding their global and regional presence in enterprise solutions.

The oligonucleotide active pharmaceutical ingredient market is predicted to grow due to tactical partnerships and new product introductions by key industry competitors. To maintain a presence in the oligonucleotide API market, organisations with creative work abilities and innovative capacity will be in place.

Increasing research on gene therapy and attractive reimbursement scenario is crucial for the growth of the market at an outstanding rate, with North America and Europe owning a considerable share of the global oligonucleotide API market.

Oligonucleotide API Industry Report Scope

Attribute

Details

Forecast Period

2022-2030

Historical Data Available for

2015-2021

Market Analysis

US$ Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa (MEA)

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • Turkey
  • South Africa
  • and GCC Countries

Key Market Segments Covered

  • API
  • Marketing Status
  • End User
  • Region

Key Companies Profiled

Pricing

Available upon Request

Key Segments of Oligonucleotide API Industry Survey

Oligonucleotide API Market by API:

  • Antisense Oligonucleotides APIs
  • Short Interfering RNA (siRNA) APIs
  • Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
  • MiRNA APIs
  • Aptamers APIs
  • CpG Oligonucleotides APIs
  • Others (ON Conjugates (NP), ShRNA, etc.)

Oligonucleotide API Market by Marketing Status:

  • Marketed
  • Clinical Trials (Clinical Phases)

Oligonucleotide API Market by End User:

  • Contract Manufacturing Organizations (CMOs)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Contract Development & Manufacturing Organizations (CDMOs)

Oligonucleotide API Market by Region:

  • North America Oligonucleotide API Market
  • Latin America Oligonucleotide API Market
  • Europe Oligonucleotide API Market
  • East Asia Oligonucleotide API Market
  • South Asia & Pacific Oligonucleotide API Market
  • Middle East & Africa (MEA) Oligonucleotide API Market

Frequently Asked Questions

Through 2030, the global oligonucleotide API market is expected to expand at a CAGR of 10.2%.

The global market for oligonucleotide APIs is valued at US$ 2.46 Bn at present.

By 2030, the global oligonucleotide active pharmaceutical ingredient market is expected to reach a value of US$ 5.36 Bn.

The North America oligonucleotide API market currently holds 39.9% share in the global market.

In North America and Europe, increased gene therapy research and a favourable reimbursement landscape are driving the market's rapid expansion.

Some of the key oligonucleotide active pharmaceutical ingredient providers are Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics., and Alnylam Pharmaceuticals, Inc.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Assessment

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Background

    4.1. Macro-Economic Factors

        4.1.1. Global GDP Growth Outlook

        4.1.2. Global Healthcare Outlook

    4.2. Forecast Factors - Relevance & Impact

        4.2.1. Research and Developmental Activities

        4.2.2. Product Formulation Advancement

        4.2.3. Key Players Historical Growth

        4.2.4. Market Consolidation Activities

        4.2.5. Growing Investment by Key Players in Product Development

    4.3. Current COVID19 Statistics and Probable Future Impact

        4.3.1. Current GDP Projection and Probable Impact

        4.3.2. Current Economic Projection as compared to 2008 financial analysis

        4.3.3. COVID19 and Impact Analysis

        4.3.4. 2022 Market Scenario

        4.3.5. Recovery Scenario – Short term, Midterm and Long Term Impact

    4.4. Market Dynamics

        4.4.1. Drivers

        4.4.2. Restraints

        4.4.3. Opportunities

5. Market Context

    5.1. Product USPs/ Features

    5.2. Product Adoption / Usage Analysis

    5.3. Regulatory Scenario

    5.4. Opportunity Analysis For The Products Under Late Stage Clinical Trial

    5.5. Revenue Breakdown by Region by Approved Market Products

    5.6. Supply-Chain Analysis

    5.7. Value Chain Analysis

6. Oligonucleotide API Market Volume (in Kg/Tons) Analysis 2015-2021 and Forecast, 2022-2030

    6.1. Historical Market Volume (Kg/Tons) Analysis, 2015-2021

    6.2. Current and Future Market Volume (Kg/Tons) Projections, 2022-2030

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Oligonucleotide API Market Value (US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030

    7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Opportunity Analysis, 2022-2030

8. Global Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030, By API Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) & Volume (Kg/Tons) Analysis By API Type, 2015-2021

    8.3. Current and Future Market Size (US$ Mn) & Volume (Kg/Tons) Analysis and Forecast By API Type, 2022-2030

        8.3.1. Antisense Oligonucleotides API

        8.3.2. Short Interfering RNA (siRNA) API

        8.3.3. Phosphorodiamidate Morpholino Oligonucleotides (PMO) API

        8.3.4. MiRNA API

        8.3.5. Aptamers API

        8.3.6. CpG Oligonucleotides API

        8.3.7. Others (ON Conjugates (NP), ShRNA, etc.)

    8.4. Market Attractiveness Analysis By API Type

9. Global Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Marketing Status, 2015-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Marketing Status, 2022-2030

        9.3.1. Marketed

        9.3.2. Clinical Trials (Clinical Phase)

    9.4. Market Attractiveness Analysis By Marketing Status

10. Global Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030, by End User

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By End User, 2015-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2030

        10.3.1. Contract Manufacturing Organizations (CMOs)

        10.3.2. Pharmaceutical & Biopharmaceutical Companies

        10.3.3. Contract Development & Manufacturing Organizations (CDMOs)

    10.4. Market Attractiveness Analysis By End User

11. Global Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030, by Region

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2030

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa

    11.4. Market Attractiveness Analysis By Region

12. North America Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        12.3.1.By Country

            12.3.1.1. U.S.

            12.3.1.2. Canada

        12.3.2. By API Type

        12.3.3. By Marketing Status

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. Latin America Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        13.3.1.By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By API Type

        13.3.3. By Marketing Status

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. Europe Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        14.3.1.By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. U.K.

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By API Type

        14.3.3. By Marketing Status

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. South Asia Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        15.3.1.By Country

            15.3.1.1. India

            15.3.1.2. Thailand

            15.3.1.3. Indonesia

            15.3.1.4. Malaysia

            15.3.1.5. Rest of South Asia

        15.3.2. By API Type

        15.3.3. By Marketing Status

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. East Asia Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By API Type

        16.3.3. By Marketing Status

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Oceania Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        17.3.1.By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By API Type

        17.3.3. By Marketing Status

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Turkey

            18.3.1.3. South Africa

            18.3.1.4. Rest of Middle East and Africa

        18.3.2. By API Type

        18.3.3. By Marketing Status

        18.3.4. By End User

    18.4. Market Attractiveness Analysis

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. Key and Emerging Countries Oligonucleotide API Market Analysis 2015-2021 and Forecast 2022-2030

    19.1. Introduction

        19.1.1. Market Value Proportion Analysis, By Key Countries

        19.1.2. Global Vs. Country Growth Comparison

    19.2. U.S. Oligonucleotide API Market Analysis

        19.2.1. By API Type

        19.2.2. By Marketing Status

        19.2.3. By End User

    19.3. Canada Oligonucleotide API Market Analysis

        19.3.1. By API Type

        19.3.2. By Marketing Status

        19.3.3. By End User

    19.4. Mexico Oligonucleotide API Market Analysis

        19.4.1. By API Type

        19.4.2. By Marketing Status

        19.4.3. By End User

    19.5. Brazil Oligonucleotide API Market Analysis

        19.5.1. By API Type

        19.5.2. By Marketing Status

        19.5.3. By End User

    19.6. U.K. Oligonucleotide API Market Analysis

        19.6.1. By API Type

        19.6.2. By Marketing Status

        19.6.3. By End User

    19.7. Germany Oligonucleotide API Market Analysis

        19.7.1. By API Type

        19.7.2. By Marketing Status

        19.7.3. By End User

    19.8. France Oligonucleotide API Market Analysis

        19.8.1. By API Type

        19.8.2. By Marketing Status

        19.8.3. By End User

    19.9. Italy Oligonucleotide API Market Analysis

        19.9.1. By API Type

        19.9.2. By Marketing Status

        19.9.3. By End User

    19.10. Spain Oligonucleotide API Market Analysis

        19.10.1. By API Type

        19.10.2. By Marketing Status

        19.10.3. By End User

    19.11. BENELUX Oligonucleotide API Market Analysis

        19.11.1. By API Type

        19.11.2. By Marketing Status

        19.11.3. By End User

    19.12. Russia Oligonucleotide API Market Analysis

        19.12.1. By API Type

        19.12.2. By Marketing Status

        19.12.3. By End User

    19.13. China Oligonucleotide API Market Analysis

        19.13.1. By API Type

        19.13.2. By Marketing Status

        19.13.3. By End User

    19.14. Japan Oligonucleotide API Market Analysis

        19.14.1. By API Type

        19.14.2. By Marketing Status

        19.14.3. By End User

    19.15. South Korea Oligonucleotide API Market Analysis

        19.15.1. By API Type

        19.15.2. By Marketing Status

        19.15.3. By End User

    19.16. India Oligonucleotide API Market Analysis

        19.16.1. By API Type

        19.16.2. By Marketing Status

        19.16.3. By End User

    19.17. ASEAN Oligonucleotide API Market Analysis

        19.17.1. By API Type

        19.17.2. By Marketing Status

        19.17.3. By End User

    19.18. Australia Oligonucleotide API Market Analysis

        19.18.1. By API Type

        19.18.2. By Marketing Status

        19.18.3. By End User

    19.19. New Zealand Oligonucleotide API Market Analysis

        19.19.1. By API Type

        19.19.2. By Marketing Status

        19.19.3. By End User

    19.20. GCC Countries Oligonucleotide API Market Analysis

        19.20.1. By API Type

        19.20.2. By Marketing Status

        19.20.3. By End User

    19.21. Turkey Oligonucleotide API Market Analysis

        19.21.1. By API Type

        19.21.2. By Marketing Status

        19.21.3. By End User

    19.22. South Africa Oligonucleotide API Market Analysis

        19.22.1. By API Type

        19.22.2. By Marketing Status

        19.22.3. By End User

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

        20.3.1. Regional Footprint by Players

        20.3.2. Product Foot print by Players

        20.3.3. Channel Foot Print by Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive (Tentative List)

        21.3.1. Agilent Technologies, Inc.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.1.4. Sales Footprint

            21.3.1.5. Strategy Overview

                21.3.1.5.1. Marketing Strategy

                21.3.1.5.2. Product Strategy

                21.3.1.5.3. Channel Strategy

        21.3.2. Bachem Holding AG

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.2.4. Sales Footprint

            21.3.2.5. Strategy Overview

                21.3.2.5.1. Marketing Strategy

                21.3.2.5.2. Product Strategy

                21.3.2.5.3. Channel Strategy

        21.3.3. CordenPharma International

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.3.4. Sales Footprint

            21.3.3.5. Strategy Overview

                21.3.3.5.1. Marketing Strategy

                21.3.3.5.2. Product Strategy

                21.3.3.5.3. Channel Strategy

        21.3.4. Integrated DNA Technologies, Inc. (Danaher Corporation)

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.4.4. Sales Footprint

            21.3.4.5. Strategy Overview

                21.3.4.5.1. Marketing Strategy

                21.3.4.5.2. Product Strategy

                21.3.4.5.3. Channel Strategy

        21.3.5. Eurofins Scientific

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.5.4. Sales Footprint

            21.3.5.5. Strategy Overview

                21.3.5.5.1. Marketing Strategy

                21.3.5.5.2. Product Strategy

                21.3.5.5.3. Channel Strategy

        21.3.6. GE Healthcare

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.6.4. Sales Footprint

            21.3.6.5. Strategy Overview

                21.3.6.5.1. Marketing Strategy

                21.3.6.5.2. Product Strategy

                21.3.6.5.3. Channel Strategy

        21.3.7. Merck KGaA

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.7.4. Sales Footprint

            21.3.7.5. Strategy Overview

                21.3.7.5.1. Marketing Strategy

                21.3.7.5.2. Product Strategy

                21.3.7.5.3. Channel Strategy

        21.3.8. Thermo Fisher Scientific

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.8.4. Sales Footprint

            21.3.8.5. Strategy Overview

                21.3.8.5.1. Marketing Strategy

                21.3.8.5.2. Product Strategy

                21.3.8.5.3. Channel Strategy

        21.3.9. RiBoBio Co.

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.9.4. Sales Footprint

            21.3.9.5. Strategy Overview

                21.3.9.5.1. Marketing Strategy

                21.3.9.5.2. Product Strategy

                21.3.9.5.3. Channel Strategy

        21.3.10. LGC Biosearch Technologies

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.10.4. Sales Footprint

            21.3.10.5. Strategy Overview

                21.3.10.5.1. Marketing Strategy

                21.3.10.5.2. Product Strategy

                21.3.10.5.3. Channel Strategy

        21.3.11. ST Pharm

            21.3.11.1. Overview

            21.3.11.2. Product Portfolio

            21.3.11.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.11.4. Sales Footprint

            21.3.11.5. Strategy Overview

                21.3.11.5.1. Marketing Strategy

                21.3.11.5.2. Product Strategy

                21.3.11.5.3. Channel Strategy

        21.3.12. Kaneka Eurogentec S.A.

            21.3.12.1. Overview

            21.3.12.2. Product Portfolio

            21.3.12.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.12.4. Sales Footprint

            21.3.12.5. Strategy Overview

                21.3.12.5.1. Marketing Strategy

                21.3.12.5.2. Product Strategy

                21.3.12.5.3. Channel Strategy

        21.3.13. Ajinomoto Co., Inc.

            21.3.13.1. Overview

            21.3.13.2. Product Portfolio

            21.3.13.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.13.4. Sales Footprint

            21.3.13.5. Strategy Overview

                21.3.13.5.1. Marketing Strategy

                21.3.13.5.2. Product Strategy

                21.3.13.5.3. Channel Strategy

        21.3.14. Bio-synthesis Inc.

            21.3.14.1. Overview

            21.3.14.2. Product Portfolio

            21.3.14.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.14.4. Sales Footprint

            21.3.14.5. Strategy Overview

                21.3.14.5.1. Marketing Strategy

                21.3.14.5.2. Product Strategy

                21.3.14.5.3. Channel Strategy

        21.3.15. STA Pharmaceutical Co., Ltd.

            21.3.15.1. Overview

            21.3.15.2. Product Portfolio

            21.3.15.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.15.4. Sales Footprint

            21.3.15.5. Strategy Overview

                21.3.15.5.1. Marketing Strategy

                21.3.15.5.2. Product Strategy

                21.3.15.5.3. Channel Strategy

        21.3.16. BioSpring GmbH

            21.3.16.1. Overview

            21.3.16.2. Product Portfolio

            21.3.16.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.16.4. Sales Footprint

            21.3.16.5. Strategy Overview

                21.3.16.5.1. Marketing Strategy

                21.3.16.5.2. Product Strategy

                21.3.16.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 02: Global Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 03: Global Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Table 04: Global Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Region

Table 05: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 06: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 07: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 08: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Table 09: Latin America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 10: Latin America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 11: Latin America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 12: Latin America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Table 13: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 14: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 15: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 16: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Table 17: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 18: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 19: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 20: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Table 21: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 22: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 23: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 24: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Table 25: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 26: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 27: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 28: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Table 29: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 30: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by API Type

Table 31: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Marketing Status

Table 32: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, by End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Oligonucleotide API Market Size (US$ Mn) Analysis, 2015–2021

Figure 02: Global Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%) Analysis, 2021–2030

Figure 03: Global Oligonucleotide API Market Absolute $ Opportunity Analysis, 2021–2030

Figure 04: Global Oligonucleotide API Market Analysis by API Type –2021 & 2030

Figure 05: Global Oligonucleotide API Market Y-o-Y Growth Projections by API Type, 2021 – 2030

Figure 06: Global Oligonucleotide API Market Attractiveness Analysis By API Type, 2021-2030,

Figure 07: Global Oligonucleotide API Market Analysis by Marketing Status –2021 & 2030

Figure 08: Global Oligonucleotide API Market Y-o-Y Growth Projections by Marketing Status, 2021 – 2030

Figure 09: Global Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Marketing Status

Figure 10: Global Oligonucleotide API Market Analysis by End User –2021 & 2030

Figure 11: Global Oligonucleotide API Market Y-o-Y Growth Projections by End User, 2021 – 2030

Figure 12: Global Oligonucleotide API Market Attractiveness Analysis 2021-2030, By End User

Figure 13: Global Oligonucleotide API Market Share Analysis (%) By Region, 2021 & 2030

Figure 14: Global Oligonucleotide API Market Y-o-Y Growth (%) By Region, 2021–2030

Figure 15: Global Oligonucleotide API Market Attractiveness Analysis 2021-2030, By Region

Figure 16: North America Oligonucleotide API Market Size (US$ Mn) Analysis, 2015-2021

Figure 17: North America Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%), 2021–2030

Figure 18: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Country

Figure 19: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by API Type

Figure 20: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, Marketing Status

Figure 21: North America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by End User

Figure 22: Latin America Oligonucleotide API Market Size (US$ Mn) Analysis, 2015-2021

Figure 23: Latin America Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%), 2021–2030

Figure 24: Latin America Medical America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Country

Figure 25: Latin America Medical America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by API Type

Figure 26: Latin America Medical America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, Marketing Status

Figure 27: Latin America Medical America Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by End User

Figure 28: Europe Oligonucleotide API Market Size (US$ Mn) Analysis, 2015-2021

Figure 29: Europe Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%), 2021–2030

Figure 30: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Country

Figure 31: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by API Type

Figure 32: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, Marketing Status

Figure 33: Europe Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by End User

Figure 34: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis, 2015-2021

Figure 35: East Asia Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%), 2021–2030

Figure 36: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Country

Figure 37: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by API Type

Figure 38: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, Marketing Status

Figure 39: East Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by End User

Figure 40: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis, 2015-2021

Figure 41: South Asia Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%), 2021–2030

Figure 42: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Country

Figure 43: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by API Type

Figure 44: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, Marketing Status

Figure 45: South Asia Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by End User

Figure 46: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis, 2015-2021

Figure 47: Oceania Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%), 2021–2030

Figure 48: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Country

Figure 49: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by API Type

Figure 50: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, Marketing Status

Figure 51: Oceania Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by End User

Figure 52: MEA Oligonucleotide API Market Size (US$ Mn) Analysis, 2015-2021

Figure 53: MEA Oligonucleotide API Market Size (US$ Mn) & Y-o-Y Growth (%), 2021–2030

Figure 54: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by Country

Figure 55: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by API Type

Figure 56: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, Marketing Status

Figure 57: MEA Oligonucleotide API Market Size (US$ Mn) Analysis 2015-2021 and Forecast 2021-2030, by End User

Figure 58: China Market Value Proportion Analysis, 2021

Figure 59: China Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 60: China. Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 61: China. Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 62: Global Vs. China Growth Comparison

Figure 63: India Market Value Proportion Analysis, 2021

Figure 64: India. Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 65: India. Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 66: India. Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 67: Global Vs. India Growth Comparison

Figure 68: Brazil Market Value Proportion Analysis, 2021

Figure 69: Brazil. Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 70: Brazil. Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 71: Brazil. Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 72: Global Vs. Brazil Growth Comparison

Figure 73: U.S Market Value Proportion Analysis, 2021

Figure 74: U.S. Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 75: U.S. Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 76: U.S. Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 77: Global Vs. U.S Growth Comparison

Figure 78: Canada Market Value Proportion Analysis, 2021

Figure 79: Canada Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 80: Canada Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 81: Canada Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 82: Global Vs. Canada Growth Comparison

Figure 83: Mexico Market Value Proportion Analysis, 2021

Figure 84: Mexico Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 85: Mexico Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 86: Mexico Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 87: Global Vs. Mexico Growth Comparison

Figure 88: Argentina Market Value Proportion Analysis, 2021

Figure 89: Argentina Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 90: Argentina Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 91: Argentina Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 92: Global Vs. Argentina Growth Comparison

Figure 93: U.K. Market Value Proportion Analysis, 2021

Figure 94: U.K. Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 95: U.K. Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 96: U.K. Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 97: Global Vs. U.K Growth Comparison

Figure 98: Germany Market Value Proportion Analysis, 2021

Figure 99: Germany Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 100: Germany Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 101: Germany Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 102: Global Vs. Germany Growth Comparison

Figure 103: France Market Value Proportion Analysis, 2021

Figure 104: France Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 105: France Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 106: France Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 107: Global Vs. France Growth Comparison

Figure 108: Italy Market Value Proportion Analysis, 2021

Figure 109: Italy Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 110: Italy Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 111: Italy Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 112: Global Vs. Italy Growth Comparison

Figure 113: Spain Market Value Proportion Analysis, 2021

Figure 114: Spain Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 115: Spain Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 116: Spain Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 117: Global Vs. Spain Growth Comparison

Figure 118: Russia Market Value Proportion Analysis, 2021

Figure 119: Russia Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 120: Russia Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 121: Russia Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 122: Global Vs. Russia Growth Comparison

Figure 123: Japan Market Value Proportion Analysis, 2021

Figure 124: Japan Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 125: Japan Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 126: Japan Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 127: Global Vs. Japan Growth Comparison

Figure 128: South Korea Market Value Proportion Analysis, 2021

Figure 129: South Korea Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 130: South Korea Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 131: South Korea Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 132: Global Vs. South Korea Growth Comparison

Figure 133: Indonesia Market Value Proportion Analysis, 2021

Figure 134: Indonesia Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 135: Indonesia Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 136: Indonesia Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 137: Global Vs. Indonesia Growth Comparison

Figure 138: Malaysia Market Value Proportion Analysis, 2021

Figure 139: Malaysia Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 140: Malaysia Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 141: Malaysia Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 142: Global Vs. Malaysia Growth Comparison

Figure 143: Thailand Market Value Proportion Analysis, 2021

Figure 144: Thailand Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 145: Thailand Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 146: Thailand Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 147: Global Vs. Thailand Growth Comparison

Figure 148: Australia Market Value Proportion Analysis, 2021

Figure 149: Australia Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 150: Australia Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 151: Australia Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 152: Global Vs. Australia Growth Comparison

Figure 153: New Zealand Market Value Proportion Analysis, 2021

Figure 154: New Zealand Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 155: New Zealand Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 156: New Zealand Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 157: Global Vs. New Zealand Growth Comparison

Figure 158: South Africa Market Value Proportion Analysis, 2021

Figure 159: South Africa Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 160: South Africa Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 161: South Africa Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 162: Global Vs. South Africa Growth Comparison

Figure 163: GCC Countries Market Value Proportion Analysis, 2021

Figure 164: GCC Countries Oligonucleotide API Market Share Analysis (%) By API Type, 2021 & 2030

Figure 165: GCC Countries Oligonucleotide API Market Share Analysis (%) By Marketing Status, 2021 & 2030

Figure 166: GCC Countries Oligonucleotide API Market Share Analysis (%) By End User, 2021 & 2030

Figure 167: Global Vs. GCC Countries Growth Comparison

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Antibiotics Active Pharmaceutical Ingredient (API) Market

Published : February 2021

Healthcare

Ibuprofen API Market

Published : April 2020

Healthcare

Small Molecule API Market

Published : March 2021

Healthcare

DNA Polymerase Market

Published : April 2021

Google translate

Oligonucleotide API Market